NCT00562458已完成不适用
ARIMIDEX Study ( Non-interventional Study to Evaluate Arimidex in Adjuvant Therapy in Partial or Complete Response or Stabilized Disease After First Line Chemotherapy in Postmenopausal Women With Advanced Breast Cancer)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 200
研究概览
简要总结
To evaluate Arimidex 6 month therapy as an adjuvant treatment in postmenopausal patients with advanced breast cancer in whom a partial or complete response or stabilized disease were obtained with first line chemotherapy, by tumoral response assessment.
研究设计
- 研究类型
- Observational
- 时间视角
- Prospective
入排标准
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients to be included in the program are that ones according to the indications specified in the Romanian anastrozole (Arimidex) approved SmPC (attached to the protocol)and who are already treated with anastrozole for at least 1 month before inclusion in this program/non-interventional study.
排除标准
- •Patients not to be included in the programme: patients who have a known hypersensitivity to anastrozole (Arimidex®) or any of its excipients.
研究者
相似试验
已完成
不适用
Quality of Life Analysis of Arimidex Treatment in Postmenopausal Patients With Breast CancerBreast CancerNCT00692289AstraZeneca1,510
已完成
3 期
ITA - Clinical Study Comparing ARIMIDEX™ With NOLVADEX™ in Women With Breast Cancer Treated With NOLVADEX for at Least 2 YearsBreast CancerNCT00286117AstraZeneca448
已完成
3 期
IBCSG VIII - Adjuvant therapy in pre- and peri-menopausal patients with node negative breast cancerCancer - BreastBreast CancerACTRN12607000037404International Breast Cancer Study Group1,200
进行中（未招募）
2 期
Clinical Study of Adjuvant Therapy on Post-menopausal Women With Breast Cancer Under the Guidance of the Results of Preoperative EndocrinotherapyBreast CancerNCT01613560Tao OUYANG404
Unknown
不适用
Effects of Adjuvant Endocrine Therapy With Aromatase Inhibitors on the Postoperative Lipid Levels in Postmenopausal Breast Cancer PatientsBreast CancerNCT02765373Chinese Academy of Medical Sciences500